

Tosoh Automated
Glycohemoglobin Analyzer
HLC-723GX

TOSOH BIOSCIENCE

The Diabetes Epidemic and the role of HbA_{1c}

Diabetes is recognised worldwide as a disease that is reaching epidemic proportions. ⁽¹⁾


IDF region	Adult Population (20-79) in 1000s	Diabetes cases (20-79) in 1000s	Diabetes national prevalence (%)	Undiagnosed Diabetics in 1000s	Undiagnosed Diabetics %	Diabetes related deaths (20-79)	Mean diabetes-related expenditure per person with diabetes (EURO)
WORLD	4,479,259	371,329	8.29 %	187,087	4.18 %	4,802,747	1,027
EUR	655,983	54,942	8.38 %	21,204	3.23 %	622,114	2,043
MENA	366,249	34,163	9.33 %	18,114	4.95 %	356,586	285
AFR	398,113	14,920	3.75 %	12,148	3.05 %	401,276	135

The significance of HbA_{1c} for the diagnosis and follow-up of diabetes has increased with the continuing rise in the number of patients. This represents a significant workload challenge to many laboratories.

How to measure HbA_{1c}?

One of the reference methods for HbA_{1c} measurement is "High Performance Liquid Chromatography", better known as "HPLC" (this method was also used in the DCCT and UKPDS trials). With this technique the different haemoglobin fractions are separated based on charge.

When using the **Tosoh Automated Glycohemoglobin Analyzer HLC-723GX (GX)** separation of the haemoglobin fractions is obtained by use of a negatively charged column and positively charged buffers that compete with the different haemoglobins to bind to the column (= cation exchange). Tosoh offers you over 35 years of world leading HPLC experience.



Why use HPLC?

Besides being the method used during the DCCT and UKPDS trials different arguments are raised in literature.

"The method of choice should measure HbA_{1c} highly precisely; should be economical, automatable and simple to perform; and should yield results that are comparable between different laboratories, ...one should use a method that meets the following conditions: The Hb variant should be recognised; and HbA_{1c}, HbA₀ and Hb variants should be separated and quantified reliably." ⁽²⁾

"The advantage of HPLC lies in its ability to separate variant haemoglobins and, in doing so, allowing better interpretation of the result!" ⁽³⁾

The Importance of low CV%

HbA_{1c} can be used for three specific applications*:

1. For identifying risk.

HbA_{1c} could be used as a tool, among other parameters, to identify individuals at risk for developing diabetes. The American Diabetes Association (ADA) suggested 5.7 – 6.4 % (39 – 47 mmol/mol) as the high risk range. ^(4,5)

2. For Diagnosis.

An international expert committee assembled by the American Diabetes Association (ADA), International Diabetes Federation (IDF), and European Association for the Study of Diabetes (EASD) has recommended the HbA_{1c} assay as the new test for the diagnosis of diabetes. An HbA_{1c} value greater than or equal to 6.5 %, or 48 mmol/mol, is used as cut-off for the diagnosis of diabetes. Diagnosis should be confirmed with a **repeat** HbA_{1c} test. ^(4,5)

3. For treatment follow-up.

Lowering HbA_{1c} to below or around 7 %, or 53 mmol/mol, has been shown to reduce micro-vascular and neuropathic complications of type 1 and type 2 diabetes. HbA_{1c} of ≥ 7 %, or 53 mmol/mol, should initiate or change therapy to reach an HbA_{1c} level of < 7 %, or 53 mmol/mol. Relevant changes in **serial** measurements of HbA_{1c} testing serve as the guide to changes in therapeutic regimes. ^(6,7)

The Coefficient of Variation (CV) determines the difference between two serial HbA_{1c} measurements.

At a medical decision point of 7 %, or 53 mmol/mol, a healthcare provider should be able to conclude that a significant difference of 0.5 %, or 5 mmol/mol, is caused by a change in glycaemic control of a patient and not by the analytical imprecision. For that reason the CV% of the method should be ≤ 2.4 %. ⁽⁸⁾

"...95 % of the laboratories using a method from Tosoh were able to meet the criteria of having an analytical CV% of ≤ 2.4 %!" ⁽⁸⁾

* Official guidelines on the use of HbA_{1c} may vary from country to country.

Stable HbA_{1c} result with variant detection in **2.2 minutes**,

The GX will deliver:

- **Precision**
Direct determination of stable HbA_{1c} with less than 1 % CV.
- **Speed**
Stable HbA_{1c} result with variant detection in 2.2 minutes.
Time to first result is 6.6 minutes.
- **Operational Simplicity**
With cap piercing, positive sample identification, automated maintenance, the GX is simplicity itself.
- **Absence of Interference**
In the presence of the most common haemoglobin variants, HbF or haemoglobin derivatives such as labile and carbamylated haemoglobin, HbA_{1c} results are unaffected.



with less than **1 % CV**. Time to first result is **6.6 minutes**.

The GX provides you exceptional Operational Simplicity...

- Cap piercing capability minimises manual handling.
- Positive sample identification via barcode reader (optional).
- Up to 10 samples per batch.
- Automated daily maintenance.
- A user friendly touch screen enables easy instrument operation.
- Simple finger tight connectors permit quick, convenient and easy replacement of columns and pre-filters.
- Constant visual monitoring of buffer consumption with customisable alarm.
- Integration to Tosoh's data management software (optional) for full data management capabilities including:
 - Patient linked result validation
 - Chromatogram review with overlay and library facility
 - Full QC-package including Levey-Jennings charts
 - Reagent logging and audit trail
 - Data storage and full result archiving



Compact
W 370 mm
D 525 mm
H 482 mm
25 kg

...and an unparalleled level of patient safety.

- Highly developed function for programming user-selectable flags to ensure easy interpretation of results.
- Unique TSKgel column and optimal column temperature control guarantee stable results.

The GX: the perfect solution for reliable diabetic patient monitoring!

- HbA_{1c} results directly determined with less than 1 % CV and reportable to 2 decimal places.
- Results unaffected by the presence of the most common haemoglobin variants or haemoglobin derivatives such as labile HbA_{1c} and carbamylated - or acetylated haemoglobin.
- HbA_{1c} results traceable to the NGSP / DCCT and IFCC.


Intra-Assay precision			Inter-Assay precision		
N = 30	Mean HbA _{1c} (%)	CV (%)	N = 91	Mean HbA _{1c} (%)	CV (%)
Normal value	4.97	0.41	Normal value	5.28	0.89
Elevated value	9.25	0.29	Elevated value	10.11	0.28

Source: Evaluation de l'automate HLC-723GX Tosoh Bioscience pour le dosage de l'hémoglobine A1c. Protocole EH12-08. Fonfrède et al. Laboratoire de biochimie métabolique, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.


Best-in-class chromatographic separation!

- Separation of labile A_{1c} from stable A_{1c} is achieved without loss of precision or resolution and without manipulating the sample or using mathematical algorithms.


Non-diabetic Patient*




HbD Patient*



HbS Patient*



HbC Patient*



* HbA_{1c} is reportable and in the presence of the most common variants the result is flagged.

Traceability to International Standards

HbA_{1c} results obtained with the G8 are traceable to the “National Glycohemoglobin Standardization Program (NGSP; DCCT-aligned)” and the “International Federation of Clinical Chemistry (IFCC)”.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 5th edn, Brussels, Belgium: International Diabetes Federation, 2011. Update 2012 on website www.idf.org.
2. Halwachs-Baumann G, Katzensteiner S, Schnedl W, Pürstner P, Pieber P, Wilders-Truschnig M: Comparative evaluation of three assay systems for automated determination of hemoglobin A1c. *Clinical Chemistry* 1997; 43(3): 511-517.
3. Chapelle JP, Teixeira J, Maisin D, Assink H, Barla G, Stroobants AK, Delzenne B, van den Eshof W: Multicentre evaluation of the Tosoh HbA1c G8 Analyser. *Clin Chem Lab Med* 2010; 48(3): 365-371.
4. The International Expert Committee. International expert committee report on the role of the A1c assay in the diagnosis of diabetes. *Diabetes Care* 2009; 32(7): 1327-1334.
5. World Health Organisation. Use of Glycated Haemoglobin (HbA1c) in the diagnosis of Diabetes Mellitus, WHO/NMH/CHP/CPM/11.1. Geneva. World Health Organisation, 2011.
6. Standards of medical care in diabetes – 2011. *Diabetes Care* 2011; 34(Suppl 1): S11-S61.
7. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for the Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009; 32:193-203.
8. Lenters-Westra E, Weykamp C, Schindhelm RK, Siebelder C, Bilo HJ, Slingerland RJ: One in five laboratories using various hemoglobin A1c methods do not meet the criteria for optimal diabetes care management. *Diabetes Technology & Therapeutics* 2011;13(4):429-433.



TOSOH

EC REP

TOSOH EUROPE N.V.

Transportstraat 4 3980 Tessenderlo - BELGIUM
Tel : +32 (0)13 66 88 30 Fax : +32 (0)13 66 47 49
www.tosohbioscience.eu



TOSOH CORPORATION BIOSCIENCE DIVISION

Shiba-Koen First Bldg. 3-8-2, Shiba, Minato-ku, Tokyo 105-8623 - JAPAN
Tel : +81-3-5427-5181 Fax : +81-3-5427-5220
www.tosoh.com